Company: BIAF
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001641172-25-001840
Chunk: 22

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 22
---
 that are not amenable to, or that we do not consider appropriate for, patent protection. The confidentiality
agreements are designed to protect our proprietary information, and the invention assignment agreements are designed to gain company
control and ownership of technologies that are developed for us by our employees, consultants, or other third parties. We seek to preserve
the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises, physical and electronic
security of our information technology systems, and non-disclosure agreements with those that produce or receive company confidential
information. While we have confidence in our agreements and security measures, either may be breached, and we may not have adequate remedies.
In addition, our trade secrets may otherwise become known or independently discovered by competitors.

Our
commercial success depends in part upon our ability to obtain and maintain patent and other proprietary protection for commercially important
technologies, inventions, and trade secrets related to our business, defend and enforce our intellectual property rights, particularly
our patent rights, preserve the confidentiality of our trade secrets, and operate without infringing valid and enforceable intellectual
property rights of others.

The
patent positions for biotechnology companies like ours are generally uncertain and can involve complex legal, scientific, and factual issues.
In addition, the coverage claimed in a patent application can be significantly reduced before a patent is issued, and its scope can be
reinterpreted and even challenged after issuance. As a result, we cannot guarantee that any of our product candidates will be protectable
or remain protected by enforceable patents. We cannot predict whether the patent applications we are currently pursuing will issue as
patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from
competitors. Any patents that we hold may be challenged, circumvented, or invalidated by third parties.

As
of December 31, 2024, we and our OncoSelect® subsidiary have a patent estate that includes 17 issued U.S. and foreign counterpart
patents including two U.S. patents and 15 foreign counterpart patents in Australia, Canada, China, France, Germany, Hong Kong, India,
Italy, Mexico, Japan, Spain, Sweden, and the United Kingdom. We and OncoSelect® own all patents and trademarks in our intellectual
property portfolio. One U.S. patent and nine counterpart foreign patents directed at diagnostic applications expire in 2030 and one foreign
patent directed at a diagnostic application expires in 2039. One U.S. patent and five